Zolbetuximab was recently approved for the treatment of GC or GEJC with CLDN18.2 positivity (moderate to strong membranous CLDN18 expression in ≥ 75% of tumor cells) in Brazil. The gene discussed is CLDN18; the disease is neoplasm.